BioCryst (BCRX) AI Stock Analysis

• Market Cap: $1.55B
• Dividend Yield: N/A
• Average Volume (3M): 3.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 36.00%
• EPS Growth: 63.50%
• Country: US
• Employees: 580
• Sector: Healthcare
• Sector Strength: 73
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 208,960,020
• 10 Day Avg. Volume: 3,436,465
• 30 Day Avg. Volume: 3,326,613
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3.70
• Price to Cash Flow (P/CF): -80.00
• P/FCF Ratio: 9.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.73
• Price Target Upside: 104.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

BioCryst's stock score reflects strong revenue growth and promising pipeline advancements, tempered by financial instability and technical uncertainty. Positive earnings call developments and corporate announcements provide optimism, yet profitability and solvency remain critical concerns.

Positive Factors

Clinical Trials

BioCryst presented the first data from the ongoing Phase 3 APeX-P trial of Orladeyo in HAE patients under 12 years showing rapid and sustained reductions in attacks with better tolerability than in the adults.

Commercial Performance

BioCryst Pharmaceuticals raised its FY25 Orladeyo sales guidance to $535-550M, driven by higher-than-expected Medicare patient coverage and new prescription demand.

Pipeline Development

The company is focusing on early-stage pipeline programs in Netherton, indicating potential growth opportunities.

Negative Factors

Operational Expenses

The stock experienced a 10% drop, likely due to an overreaction to higher-than-expected 4Q operational expenses.

Tariff Impacts

There are concerns about potential tariff impacts which could affect the company's operations.

BioCryst Business Overview & Revenue Model

Company Description

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the design and development of novel, oral, and small-molecule medicines. Headquartered in Durham, North Carolina, BioCryst operates in the pharmaceutical and healthcare sectors, primarily targeting rare diseases. The company's core products include Orladeyo (berotralstat), an oral medication for the prevention of hereditary angioedema (HAE) attacks, and other pipeline candidates aimed at treating rare diseases.

How the Company Makes Money

BioCryst Pharmaceuticals makes money through the sale of its approved drug, Orladeyo, which is used to prevent attacks in patients with hereditary angioedema (HAE). Revenue is primarily generated from product sales and licensing agreements. The company enters into partnerships and collaborations to license its proprietary technology and compounds, providing additional revenue streams through upfront payments, milestone payments, and royalties. Furthermore, BioCryst invests in research and development to expand its pipeline of drug candidates, which may lead to future revenue opportunities upon successful development and commercialization.

BioCryst Financial Statement Overview

Summary

BioCryst shows strong revenue growth and impressive gross margins, but the ongoing unprofitability, negative equity, and high leverage are concerning. Improvements in operating cash flows offer some optimism, yet the firm's financial instability remains a critical issue.

Income Statement

BioCryst has exhibited significant revenue growth, with a 36% increase from 2023 to 2024, and a notable 110% growth since 2020. The gross profit margin is strong at approximately 97%, indicating effective cost management relative to revenue. However, the company remains unprofitable, with a negative net profit margin of -19.7% in 2024, although this is an improvement from previous years. The negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company has a concerning balance sheet with negative stockholders' equity, which suggests potential financial instability. Although the debt-to-equity ratio is not calculable due to negative equity, the high total liabilities relative to assets imply high leverage. The equity ratio of -97% in 2024 highlights this imbalance. These factors indicate potential risks related to solvency and financial flexibility.

Cash Flow

Operating cash flow has improved, reducing from -$95 million in 2023 to -$52 million in 2024. However, free cash flow remains negative, reflecting ongoing cash burn. The free cash flow to net income ratio and operating cash flow to net income ratio are both negative, indicating that cash generation remains a challenge. Despite these issues, the company has managed to grow its free cash flow by 46% year-over-year.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
450.71M	331.41M	270.83M	157.17M	17.81M
	Gross Profit
438.44M	326.75M	264.23M	149.91M	16.14M
	EBIT
-2.54M	-103.71M	-148.44M	-177.72M	-174.76M
	EBITDA
12.81M	-116.33M	-143.85M	-121.74M	-167.56M
	Net Income Common Stockholders
-88.88M	-226.54M	-247.12M	-184.06M	-196.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
320.85M	388.99M	442.39M	514.43M	300.37M
	Total Assets
490.42M	516.96M	550.00M	588.15M	334.71M
	Total Debt
12.82M	848.71M	741.45M	593.24M	124.72M
	Net Debt
-91.89M	714.50M	436.69M	88.85M	-147.41M
	Total Liabilities
966.35M	972.49M	844.60M	695.14M	353.98M
	Stockholders Equity
-475.93M	-455.53M	-1.45B	-1.21B	-1.02B
Cash Flow		Free Cash Flow
-52.02M	-97.31M	-163.20M	-144.54M	-137.73M
	Operating Cash Flow
-52.02M	-95.14M	-161.85M	-142.16M	-137.22M
	Investing Cash Flow
52.59M	-131.50M	-128.24M	15.80M	-6.86M
	Financing Cash Flow
-5.76M	32.48M	88.03M	359.67M	302.70M

BioCryst Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCRX, the sentiment is Negative. The current price of 7.22 is below the 20-day moving average (MA) of 7.33, below the 50-day MA of 7.95, and below the 200-day MA of 7.70, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 47.41 is Neutral, neither overbought nor oversold. The STOCH value of 85.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCRX.

BioCryst Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MNKD	58 Neutral	$1.41B	49.51	-35.00%	―	43.50%	―
AGIO	56 Neutral	$1.59B	2.38	57.29%	―	36.07%	―
BCRX	52 Neutral	$1.55B	―	18.68%	―	36.00%	63.50%
ARWR	50 Neutral	$1.77B	―	-600.68%	―	-98.62%	-86.21%
KYMR	50 Neutral	$1.65B	―	-36.38%	―	-40.11%	-17.79%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
IRON	41 Neutral	$1.43B	―	-27.73%	―	―	-14.19%

BioCryst Corporate Events

BioCryst Appoints CEO as Interim CFO Amid Transition

On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer and Interim Principal Accounting Officer, Anthony Doyle, effective April 9, 2025. To ensure a smooth transition, Doyle will provide consulting services until May 31, 2025. Subsequently, on April 7, 2025, the company’s Board appointed CEO Jon P. Stonehouse as the Interim CFO and Interim Principal Accounting Officer. The company has also engaged a former biotechnology CFO as a consultant to assist during the transition while searching for a permanent CFO.

Spark’s Take on BCRX Stock

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst’s stock score reflects strong revenue growth and promising pipeline advancements, tempered by financial instability and technical uncertainty. Positive earnings call developments and corporate announcements provide optimism, yet profitability and solvency remain critical concerns.

To see Spark’s full report on BCRX stock, click here.

BioCryst CFO Anthony Doyle Resigns Effective April 2025

On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer, Anthony Doyle, effective April 9, 2025. Doyle, who has been with the company since April 2020, played a crucial role during the global launch of ORLADEYO and in strengthening the company’s financial position as it nears profitability. His departure is not due to any disagreements with the company, and he will remain in his role until April 9 to ensure a smooth transition. The company has initiated a search for a new CFO.

BioCryst Faces Patent Challenge Amidst Strong Growth

In January 2025, BioCryst received a notice from Annora Pharma, challenging the patents of its drug ORLADEYO, with potential implications for its market exclusivity in the U.S. Despite this, BioCryst reported strong financial results for 2024, with significant revenue growth and an optimistic outlook for 2025. The company is expanding its pipeline with new clinical trials and aims to further increase ORLADEYO’s accessibility and market reach, particularly for pediatric patients with HAE.